31 results about "Estrogen-related receptor alpha" patented technology

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention discloses application of carnosic acid in preparing an ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and a medicine for treating osteoporosis. Through in-vitro experiments, the inventor finds that carnosic acid is an effective ERRalpha expression inhibitor and is capable of inhibiting expression of related osteoporosis markers in osteoporosis cell models; in-vivo experiments show that due to adoption of the carnosic acid, physiological phenomena (such as tibia BV / TV reduction, tibia Tb.Th reduction, tibia Tb.N reduction, tibia Tb.SP increase and tibia SM1 increase) caused by mouse ovary excision are reversed to a certain extent, then bone defects (such as bone substance reduction and / or microstructure degradation of bone) caused by estrogen deficiency symptoms can be treated, and the carnosic acid has the prospect of being developed into medicines for treating osteoporosis caused by menopause.

The invention discloses a novel 4-bromophenylurea compound with formula I for regulating estrogen-related receptor activity, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.

The invention discloses a novel N-p-tolyl-benzamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.

The present invention discloses a compound of novel 2-benzyloxy-benzoic acid esters with formula I for regulating the activity of estrogen-related receptors, its pharmaceutically acceptable salt and its application. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.

The invention discloses a novel N-phenyl-benzamide compound with formula I for regulating estrogen-related receptor activity, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.

The invention discloses a novel 3-methoxyphenyl-benzamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt and applications thereof. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.

The invention discloses a novel estrogen-related receptor alpha (ERR alpha) inhibitor, which is a compound of a formula I and pharmaceutically acceptable salt or solvate thereof. A pharmaceutical composition containing the compound can be used for preparing medicines for preventing and treating diseases including mammary cancer, cervical carcinoma, ovarian cancer, prostatic cancer, stomach cancer, colon cancer and the like.

The invention discloses a novel 2-benzyloxy-phenyl formic acid ester compound for regulating activity of estrogen-related receptor with a formula I as well as pharmaceutically acceptable salts and applications thereof. The compound and pharmaceutically acceptable salts are used for preparing activity of ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRalpha), and are used for preparing medicaments for preventing and treating breast cancer, prostatic cancer, stomach cancer, colorectal carcinoma, ovarian cancer, cervical carcinoma and other malignant tumors.

The invention discloses a novel dipoxyphenyl-methanesulfonamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention discloses a novel 3-methoxybenzyl-benzamide compound, as shown in a formula I which is described in the specification, for adjusting the activity of an estrogen-related receptor alpha and a pharmaceutically salt thereof, and medical application thereof. The compound and the pharmaceutically salt thereof can be used for preparing drugs capable of adjusting the activity of the estrogen-related receptor alpha (ERR-alpha) and preventing and treating malignant tumors like breast cancers, prostatic cancers, stomach cancers, colorectal cancers, ovarian cancer and cervical cancers.

The invention discloses a novel 3-bromophenylurea compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.

The invention discloses a novel 3-methoxybenzyl-benzamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt and applications thereof. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.